anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
DNA damage induced by oxidative stress during cardiac hypertrophy activates the ataxia telangiectasia mutated (ATM)-mediated DNA damage response (DDR) signaling, in turn aggravating the pathological cardiomyocyte growth. This study aims to identify the functional associations of long noncoding RNA (lncRNAs) with cardiac hypertrophy and DDR. The altered ventricular lncRNAs in the mice between sham and transverse aortic constriction (TAC) group were identified by microarray analysis, and a novel lncRNA AK144717 was found to gradually upregulate during the development of pathological cardiac hypertrophy induced by TAC surgery or angiotensin II (Ang II) stimulation. Silencing AK144717 had a similar anti-hypertrophic effect to that of ATM inhibitor KU55933 and also suppressed the activated ATM-DDR signaling induced by hypertrophic stimuli. The involvement of AK144717 in DDR and cardiac hypertrophy was closely related to its interaction with HMGB1, as silencing HMGB1 abolished the effects of AK144717 knockdown. The binding of AK144717 to HMGB1 prevented the interaction between HMGB1 and SIRT1, contributing to the increased acetylation and then cytosolic translocation of HMGB1. Overall, our study highlights the role of AK144717 in the hypertrophic response by interacting with HMGB1 and regulating DDR, hinting that AK144717 is a promising therapeutic target for pathological cardiac growth.
The BION™ is a novel implantable neuromuscular stimulator whose intended use in this study is to reanimate the shoulder muscles of stroke survivors with shoulder subluxation. Strokes are considered to be the most important cause of adult disability in North America, with 500,000 new cases per year in the U.S. (National Stroke Association) and 45,000 in Canada (Langton-Hewer, 1990; Shuaib \& Hachinski, 1991). Three-quarters of these patients survive and half of the survivors have substantial muscle weakness after 6 months (Gresham et al., 1979) with little chance of spontaneous recovery (Anderson, 1990; Bonita \& Beaglehole, 1988). The most commonly affected region in the early phases of recovery is the shoulder; 80% of hemiplegic stroke patients suffer from shoulder subluxation and associated chronic pain (Smith et al., 1980). The shoulder muscles that are normally active tonically are flaccidly paralyzed; the weight of the pendant arm gradually stretches and damages the atrophic muscles and ligaments, allowing the head of the humerus to descend out of the glenoid fossa. This results in chronic shoulder pain that is difficult to treat and tends to obstruct physical therapy directed toward regaining some use of the paretic arm. Our hypothesis is that electrical stimulation delivered by the BIONs should be fundamentally equivalent to muscle activation achieved voluntarily or by transcutaneous electrical nerve stimulation (TENS), but that the BIONs will prove to be a more clinically acceptable and effective approach. The BION system consists of the BION implants themselves, a controller that is operated by the study participant, and fitting hardware and software used by the clinician to implant, test, and program BION function.

In this study, the BION will be used to reanimate the shoulder muscles of stroke survivors experiencing shoulder subluxation. The objective of this study is to evaluate the safety and efficacy of intramuscular stimulation of BIONs to correct established, symptomatic shoulder subluxation in chronic stroke survivors. The results of intramuscular stimulation by BIONs will be compared with the results of treatment with conventional therapy: surface stimulation.

Degree of shoulder subluxation will be the primary outcome measure for the study. We have included other (secondary) outcome measures (i.e., muscle strength, range of motion, functional activity, spasticity/tone, subject satisfaction and pain) which may reveal secondary benefits of treatment with BIONs. The investigation is expected to last up to 21 weeks for each study participant. The study will be completed over a 5-year period.
Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
The number of patients with malignant tumors is increasing in China, and venous access ports have unique advantages for chemotherapy. Currently, China's research on venous access port-mediated kinesiophobia is still in the developing stage. Using the combination of subjective words and freedom words, and based on literature traceability methods, China National Knowledge Infrastructure (CNKI), Wanfang, Vipp, Chinese Biomedical Database (CBM), Web of Science, The COCHRANE LIBRARY, Embase, and PubMed were searched. Relevant articles published from the construction of the database to October 30, 2023, were identified. Based on the many articles and analyses, the methods of assessing kinesiophobia in malignant tumors patients using venous access port, the related influencing factors and the preventive and intervention strategies were collated. We found 33 articles examining kinesiophobia in oncology patients, of which 4 were specifically conducted on patients with malignant tumors using VAPs or PICCs. The relevant preventive and therapeutic experiences regarding kinesiophobia in cancer patients with VAP still need improvement. Nursing staff can use assessment tools such as the Tampa Rating Scale for Kinesiophobia, the Fear Avoidance Beliefs Questionnaire, and the Cancer Fatigue Scale to reasonably and effectively assess kinesiophobia among patients with malignant tumors who use VAPs. Attention should be paid to the mechanisms and roles of demographic factors, pain and foreign body sensation, cancer fatigue, pain management strategies, and other factors influencing kinesiophobia. This study provides advice to nursing staff for the management of VAP. Such considerations may reduce the complications of kinesiophobia and improve the quality of life of patients.
PURPOSE:To prepare the title granules having low side effects caused by the active surface group of the granule, by reacting an aldehyde-containing polymer particles useful as a medicine, etc., with an active hydrogen-containing polymer. CONSTITUTION:Swollen polymer particles containing an aldehyde are reacted with an aqueous solution of a polymer containing active hydrogen, pref. in the presence of a catalyst, at 10-90 deg.C, to obtain granules containing active substance and having an inert surface-protecting layer. The aldehyde-containing polymer is, e.g. dialdehyde-derivative of cellulose, dextrin, etc., and the active hydrogen-containing polymer is albumin, gelatin, etc. For example, the side effects of dialdehyde starch, i.e. bonding with the proteins in the digestive tracts, can be eliminated while maintaining its activity to remove the urea, ammonia, etc. in blood, the intestines, etc.
The Pilates Group completed a 10-week. The intervention was performed in 20 sessions. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week .
Changes in the nervous system are related to a wide range of mental disorders, which include neurodevelopmental disorders (NDD) that are characterized by early onset mental conditions, such as schizophrenia and autism spectrum disorders and correlated conditions (ASD). Previous studies have shown distinct genetic components associated with diverse schizophrenia and ASD phenotypes, with mostly focused on rescuing neural phenotypes and brain activity, but alterations related to vision are overlooked. Thus, as the vision is composed by the eyes that itself represents a part of the brain, with the retina being formed by neurons and cells originating from the glia, genetic variations affecting the brain can also affect the vision. Here, we performed a critical systematic literature review to screen for all genetic variations in individuals presenting NDD with reported alterations in vision. Using these restricting criteria, we found 20 genes with distinct types of genetic variations, inherited or de novo, that includes SNP, SNV, deletion, insertion, duplication or indel. The variations occurring within protein coding regions have different impact on protein formation, such as missense, nonsense or frameshift. Moreover, a molecular analysis of the 20 genes found revealed that 17 shared a common protein-protein or genetic interaction network. Moreover, gene expression analysis in samples from the brain and other tissues indicates that 18 of the genes found are highly expressed in the brain and retina, indicating their potential role in adult vision phenotype. Finally, we only found 3 genes from our study described in standard public databanks of ophthalmogenetics, suggesting that the other 17 genes could be novel target for vision diseases.
The present invention belongs to the field of medical biotechnology, and particular relates to a Reticulocyte Growth Factor (RGF) and a preparing method and application thereof. The factor is separated and purified from impurities of ± 1 -antitrypsin (from human plasma), and the fragment of a precursor of the antitrypsin is determined, and has very high function of promoting the generation of the reticulocyte of mice. Monoclonal antibody of EPO is not combined with the reticulocyte growth factor, which is labeled with I 125 , after the reticulocyte growth factor is combined with surface receptors of mouse bone marrow cells, the EPO cannot compete with the reticulocyte growth factor. The EPO and RGF are labeled with different fluorochromes, and it is proved that they have different receptors. The factor and EPO are injected into the mice or aplastic anemia mice, and an obvious synergistic effect for promoting the generation of the reticulocyte, red cell and leukocyte is generated. The reticulocyte growth factor can be used for preparing the medicine for treating severe anemia.
PURPOSE:To obtain a cosmetic for hair, capable of giving an excellent water- and oil-repellency, maintaining stability of the product, exhibiting a stain- proofing property and a dry touch and also improved in style retention by using a relatively low-cost perf luoroalkyl alcohol. CONSTITUTION:This cosmetic for hair contains a perfluoroalkyl alcohol represented by formula I [R1 is a straight- or branched-chain perfluoroalkyl or a omega-H-perfluoroalkyl of the formula H(CF2)t [(t) is an arbitrary integer]]. As the perfluoroalkyl, a compound of formula II [(n) is 7 to 19] is especially preferable. It is recommendable that the content of the perfluoroalkyl alcohol is 0.01 to 20wt.%. In addition, a silicone or a carbon-based lubricant is recommendably further added to this cosmetic. Further, a surfactant or a solvent may be added thereto. This cosmetic can prevent adhesion of an oily stain such as head sebum, a dust, a mote, etc.
FIELD: medicine, gastroenterology, endocrinology. SUBSTANCE: method involves administration to patients of preparation quamatel (famotidine) in the dose 80 mg orally, 2 time per 24 h for 3 weeks, not less. Method provides reliable decrease of blood glucose concentration and increase of the level of plasma blood immunoreactive insulin in combination with effective ulcer scarring. Invention can be used in treatment of patients with diabetes mellitus type II with exacerbation of chronic gastroduodenal ulcers. EFFECT: enhanced effectiveness of treatment. 1 tbl
Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
A method is described for the creation of novel isoforms of the enzyme glutathione S-transferase which have enhanced activity in host cells against specific toxic agents. The method includes site directed mutagenesis and selection with the targeted agent in the host cells. The sites of directed mutagenesis is the site of electrophile binding by the native form of the enzyme. This site has proven susceptible to manipulation without loss of enzymatic activity. Various techniques for enhancing the expression, activity, or localization of the expressed enzyme in mammalian cells are described. Genes for the mutant isoforms of the enzyme may be useful in cancer therapeutics to confer upon selected groups of cells heightened resistance to antineoplastic agents.
PURPOSE: To obtain the subject high-yield product formulated with 100% of the active ingredient, simplified in production process and obviated in the necessity of its sterilization, by coarsely grinding a stock such as a crude drug followed by pulverization and then directly tableting the resultant fine particles. CONSTITUTION: First, a stock of crude drug such as Panax ginseng C.A. Meyer is coarsely ground. Subsequently, the resultant coarse granules are pulverized into fine particles (pref. 0.5-10μm in diameter) which are then directly tableted to obtain the objective product. The pulverization is pref. carried out as follows: a jet mill is charged with the coarsely ground particles under supersonic air jet and the particles are ground into fine particles through mutual collision and their collision with the wall. It is recommended that the particles be sterilized along with the pulverization by heat generated due to high-speed rotation of the jet mill.
Stroke occurs as a result of ischemic injury to neural tissue, as a result of cardiogenic or artery to artery embolism or intracranial arterial thrombosis. The traditional vascular risk factors, namely hypertension, diabetes mellitus, tobacco smoking, family history and hyperlipidemia as well as atrial fibrillation are major determinants of stroke risk. Obstructive sleep apnea (OSA) has been shown to be a risk factor for hypertension and,although the association is less strong, atherosclerotic heart disease.There is a high prevalence of OSA amongst stroke patients, on the order of 60 to 70%, which is tenfold higher than in the general healthy population. Recently, it has been shown that, in stroke patients undergoing inpatient rehabilitation,the presence of OSA predicts both a poor functional outcome and greater length of hospitalization in the rehabilitation unit, even after adjustment for stroke severity.

We propose to examine the effect of CPAP therapy on the neuropsychological and functional outcomes of stroke patients with OSA admitted to the Toronto Rehabilitation Institute Stroke Rehabilitation Unit in a prospective, randomized study. We hypothesize that, in stroke patients with OSA, CPAP therapy will improve indices of vigilance, attention, and cognitive performances well as motor function(as it does in OSA patients without stroke)when compared to those not treated with CPAP. Furthermore,we hypothesize that the outcome of rehabilitation, as assessed by neuropsychological and motor indices, will be improved in these patients.
Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
BACKGROUND: Cancer associated cachexia is characterized by the significant loss of adipose tissue, leading to devastating weight loss and muscle wasting in the majority of cancer patients. The effects and underlying mechanisms of degradation metabolites on adipocytes in cachectic patients remain poorly understood. To address this knowledge gap, we conducted a comprehensive study combining lipidomic analysis of subcutaneous and visceral adipose tissue with transcriptomics data from the database to investigate the mechanisms of lipid regulation in adipocytes.
METHODS: We collected subcutaneous and visceral adipose tissue samples from cachectic and noncachectic cancer patients. Lipidomic analysis was performed to identify differentially expressed lipids in both types of adipose tissue. Additionally, transcriptomics data from the GEO database were analyzed to explore gene expression patterns in adipocytes. Bioinformatics analysis was employed to determine the enrichment of differentially expressed genes in specific pathways. Furthermore, molecular docking studies were conducted to predict potential protein targets of specific lipids, with a focus on the PI3K-Akt signaling pathway. Western blot analysis was used to validate protein levels of the identified target gene, lysophosphatidic acid receptor 6 (LPAR6), in subcutaneous and visceral adipose tissue from cachectic and noncachectic patients.
RESULTS: Significant lipid differences in subcutaneous and visceral adipose tissue between cachectic and noncachectic patients were identified by multivariate statistical analysis. Cachectic patients exhibited elevated Ceramides levels and reduced CerG2GNAc1 levels (P < 0.05). A total of 10 shared lipids correlated with weight loss and IL-6 levels, enriched in Sphingolipid metabolism, GPI-anchor biosynthesis, and Glyceropholipid metabolism pathways. LPAR6 expression was significantly elevated in both adipose tissues of cachectic patients (P < 0.05). Molecular docking analysis indicated strong binding of Phosphatidylethanolamine (PE) (18:2e/18:2) to LPAR6.
CONCLUSIONS: Our findings suggest that specific lipids, including PE(18:2e/18:2), may mitigate adipose tissue wasting in cachexia by modulating the expression of LPAR6 through the PI3K-Akt signaling pathway. The identification of these potential targets and mechanisms provides a foundation for future investigations and therapeutic strategies to combat cachexia. By understanding the underlying lipid regulation in adipocytes, we aim to develop targeted interventions to ameliorate the devastating impact of cachexia on patient outcomes and quality of life. Nevertheless, further studies and validation are warranted to fully elucidate the intricate mechanisms involved and translate these findings into effective clinical interventions.
FIELD: medicine, pharmacology, dermatology, cosmetology. SUBSTANCE: new preparation is suggested for apoptosis rate increase in tumor cells, in pre- tumor cells and thymocytes. Such preparation is represented by an agonist-ligand specific for RAR-γ,- type receptors. The method enables to increase the number of medicinal preparations to treat and prevent the cancer, decrease effects resulting in transplant's detachment. Moreover, the present innovation could be used to prevent and treat skin aging. EFFECT: higher efficiency of therapy. 12 cl, 2 ex, 1 tbl
Filariasis is a chronic disease where parasitic worms survive in human hosts even for decades and lead to complications like lymphedema and elephantiasis. Despite the persistent existence of filarial parasites in human hosts, fatal and thrombotic complications are not known, unlike other parasitic diseases like malaria. This suggests that filarial parasites might be affecting the host's platelet functions. This study was conducted to examine platelet functions in confirmed filariasis patients and healthy controls. Results showed that filariasis patients had larger platelets, inhibited aggregation, and slower speed of aggregation, compared to controls. However, in vivo markers of platelet activation and degranulation (beta thromboglobulin and soluble P-selectin) were not affected. Observations suggested that there is increased platelet turnover, cellular apoptosis and inhibited platelet functions in filariasis patients compared to controls. Platelet function inhibition was not associated with the duration of disease, lymphedema-affected organs, or gender of patients. This study confirms that filarial parasites modulate platelet functions in human hosts.
For escalation part different dose levels of BAY2965501 are planned in combination with 200mg pembrolizumab. BAY2965501 will be taken in combination with 200mg pembrolizumab every 3 weeks.
INTRODUCTION: By administering inferior vena cava (IVC) directed fluid, it is possible to avoid the use of additional fluid and fluid overload in patients with septic shock (SS) and sepsis-induced hypoperfusion (SIH).
METHODOLOGY: In patients with SIH and SS, we conducted prospective observational research on fluid therapy. A time-motion trace of the IVC diameter was created using M-mode imaging. The ability to predict fluid responsiveness was based on the IVC collapsibility index (cIVC) > 40%. Participants were randomised into 2 groups using a permuted block-of-four randomization list, with the investigators being blinded prior to patient allocation. They were split equally between the usual-care (UC) group, which received sepsis-guided fluid treatment, and the interventional ultrasound-guided fluid therapy (UGFT) group.
RESULTS: The average age of the participants was 63.2 years (62.8 years for the UGFT group and 63.7 years for the UC group). Co-morbid health conditions were practically the same in both arms at baseline. Prior to enrolment, both groups received the same quantity of fluid as part of resuscitation (UGFT arm received 2.4 0.6 L, UC group received 2.2 0.7 L). The UGFT group outperformed the UC group with a P value of 0.02 due to a significantly lower positive fluid balance after 72 hours of ICU discharge (-1.37 L), which rendered the UGFT group superior to the UC group. Even after accounting for the fluids consumed before enrolment, there was still a sizable difference in the fluids infused. When the pre-enrolment fluids were counted at 72 hours, UGFT participants still displayed a decreased positive fluid balance. However, there was no discernible difference in the 30-day mortality rate overall (6.3% difference, UGFT: 15.7%, and UC: 22.0%).
CONCLUSIONS: In contrast to the UC group, the UGFT arm of our study demonstrated a statistically significant benefit of Point of Care USG (POCUS) guided fluid therapy during resuscitation in sepsis in reducing the positive fluid balance in 72 hours, preventing fluid overload, and reducing the need for dialysis and invasive ventilation. However, there was no statistically significant variation in the 30-day mortality rate.
Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
The invention provides a refined compound preparation of mal moth powder and the production method. The method is aimed not to destroy the biological hormone in male moth, so as to strengthen the pharmacglocical effect and make it convenient to use and store. The compound preparation is a popular invigorating tonic which is healthy for kidney, brain and marrow. The invention is characterized in that the male moth powder is pulverized and immersed in white wine to extract the juvenile hormone other effective contents. The leaching solution is added with medical starch solution and extract of nine traditional Chinese medicines, i. e. cnidium monnieri, dodder, fenugreek seed, Chinese chive seed, morinda officinalis how, epimedium brevicornum, boschniakia rossiga, alpinia oxyphylla miq. fruit and summer squash, mixed and high-speed centrifugal spray dried to get the final product.